JPRN-jRCTs041220129招募中2 期
Efficacy of nicotinamide mononucleotide (NMN) for tinnitus
Takakura Hiromasa0 个研究点目标入组 60 人开始时间: 2023年1月27日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 80age old（—）
- 性别
- All
入选标准
- •1) The first onset chronic, persistent, and subjective unilateral tinnitus whose duration is 2-18 months.
- •2) Age-related sensorineural hearing loss, with a hearing loss no less than 30 dB at 4,000 Hz or at 8,000 Hz
- •3) THI-12 total score no less than 9 and TRSw total score no less than 12
- •4) HADS depression score no more than 14 and HADS anxiety score no more than 14
排除标准
- •a. Person with past or current malignant tumor
- •b. Person with severe comorbidities, such as heart, liver, kidney, blood, or mental diseases
- •c. Person with allergy against medicine or the test food
- •d. Pregnant, unwilling to practice contraception during the study, or lactating female
- •e. Person with middle ear disease
- •f. Person with conductive hearing loss, mixed hearing loss, or sensorineural hearing loss excluding age-related hearing loss
- •g. Person taking drug or supplement which contains nicotinamide, nicotinic acid, or NMN
- •h. Person who is not judged as not qualified by the medical doctor.
研究者
相似试验
已完成
1 期
Assessment of the safety of nicotinamide mononucleotide (NMN) in healthy subjects; phase I study. The clinical trial to evaluate metabolic-syndrome-related parameters to develop NMN as Foods with Function Claims.healthy subjectsJPRN-UMIN000021309Keio University School of Medicine10
招募中
1 期
Pilot study of safety and efficacy of nicotinamide (vitamin B3) in OPA1 Dominant Optic Atrophy -NICOPA1-TODominant Optic AtrophyCTIS2023-506214-52-00Centre Hospitalier Universitaire D Angers25
招募中
不适用
The Effeciency of NMN in Improving IVF/ICSI-ET Pregnancy Outcomes in Patients With DORDiminished Ovarian ReserveNCT06426355Peking University Third Hospital200
招募中
Unknown
Evaluation of the effects of nicotineamide mononucleotide administered intravenously to healthy subjects.healthy subjectsJPRN-UMIN000049123TOKYO GINZA WELLNESS & AGING CLINIC20
进行中（未招募）
1 期
Efficacy and tolerability of nicotinamide as add-on therapy compared to placebo in dialysis-dependent patients with elevated phosphat levelDialysis-dependent patients with hyperphosphatemiaMedDRA version: 17.0Level: LLTClassification code 10020712Term: HyperphosphatemiaSystem Organ Class: 100000004861EUCTR2013-000488-95-PLMEDICE Arzneimittel Pütter GmbH & Co. KG700